INMB INMUNE BIO INC Product Launches 8-K Filing 2025 - Trial Update Inmune Bio Inc. announced the completion of the third and highest dose cohort of its Phase I trial for INKmune, a therapy for metastatic castration-resistant prostate cancer, enabling the start of the Phase II high dose cohort.Get access to all SEC 8-K filings of the INMUNE BIO INC